|
1
|
Long JR, Shu XQ, Cai Q, Wen W, Kataoka N,
Gao YT and Zheng W: CYP19A1 genetic polymorphisms may be associated
with obesity-related phenotypes in Chinese women. Int J Obes
(Lond). 31:418–423. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Polyzos SA, Kountouras J and Mantzoros CS:
Adipose tissue, obesity and non-alcoholic fatty liver disease.
Minerva Endocrinol. 42:92–108. 2017.PubMed/NCBI
|
|
3
|
Roberts CK, Hevener AL and Barnard RJ:
Metabolic syndrome and insulin resistance: Underlying causes and
modification by exercise training. Compr Physiol. 3:1–58.
2013.PubMed/NCBI
|
|
4
|
Turer CB, Brady TM and de Ferranti SD:
Obesity, hypertension, and dyslipidemia in childhood are key
modifiable antecedents of adult cardiovascular disease: A call to
action. Circulation. 137:1256–1259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abderrahmani A, Yengo L, Caiazzo R,
Canouil M, Cauchi S, Raverdy V, Plaisance V, Pawlowski V, Lobbens
S, Maillet J, et al: Increased hepatic PDGF-AA signaling mediates
liver insulin resistance in obesity associated type 2 diabetes.
Diabetes. 67:1310–1321. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kenchaiah S, Evans JC, Levy D, Wilson PW,
Benjamin EJ, Larson MG, Kannel WB and Vasan RS: Obesity and the
risk of heart failure. N Engl J Med. 347:305–313. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wahba IM and Mak RH: Obesity and
obesity-initiated metabolic syndrome: Mechanistic links to chronic
kidney disease. Clin J Am Soc Nephrol. 2:550–562. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Heredia FP, Gómez-Martínez S and Marcos
A: Obesity, inflammation and the immune system. Proc Nutr Soc.
71:332–338. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cancello R and Clement K: Is obesity an
inflammatory illness? Role of low-grade inflammation and macrophage
infiltration in human white adipose tissue. BJOG. 113:1141–1147.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Graziani F, Cialdella P, Liuzzo G, Basile
E, Brugaletta S, Pedicino D, Leccesi L, Guidone C, Iaconelli A,
Mingrone G, et al: Cardiovascular risk in obesity: Different
activation of inflammation and immune system between obese and
morbidly obese subjects. Eur J Intern Med. 22:418–423. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vors C, Couillard C, Paradis M, Gigleux I,
Marin J, Vohl M, Couture P and Lamarche B: Supplementation with
resveratrol and curcumin does not affect the inflammatory response
to a high-fat meal in older adults with abdominal obesity: A
randomized, placebo-controlled crossover trial. J Nutr.
148:379–388. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS,
Lee MR, Oh GT, Park HS, Lee KU, Lane MD and Kim JB: Berberine
improves lipid dysregulation in obesity by controlling central and
peripheral AMPK activity. Am J Physiol Endocrinol Metab.
296:E812–E819. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rossi EL, Khatib SA, Doerstling SS, Bowers
LW, Pruski M, Ford NA, Glickman RD, Niu M, Yang P, Cui Z, et al:
Resveratrol inhibits obesity-associated adipose tissue dysfunction
and tumor growth in a mouse model of postmenopausal claudin-low
breast cancer. Mol Carcinog. 57:393–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pan J, Xu T, Xu F, Zhang Y, Liu Z, Chen W,
Fu W, Dai Y, Zhao Y, Feng J and Liang G: Development of
resveratrol-curcumin hybrids as potential therapeutic agents for
inflammatory lung diseases. Eur J Med Chem. 125:478–491. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zong Y, Sun L, Liu B, Deng YS, Zhan D,
Chen YL, He Y, Liu J, Zhang ZJ, Sun J and Lu D: Resveratrol
inhibits LPS-induced MAPKs activation via activation of the
phosphatidylinositol 3-kinase pathway in murine RAW 264.7
macrophage cells. PLoS One. 7:e441072012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee SM, Zhang Y, Tsuchiya H, Smalling R,
Jetten AM and Wang L: Small heterodimer partner/neuronal PAS domain
protein 2 axis regulates the oscillation of liver lipid metabolism.
Hepatology. 61:497–505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Latifi SM, Karandish M, Shahbazian H, Taha
JM, Cheraghian B and Moradi M: Prevalence of Metabolically Healthy
Obesity (MHO) and its relation with incidence of metabolic
syndrome, hypertension and type 2 diabetes amongst individuals aged
over 20 years in Ahvaz: A 5 year cohort study (2009–2014). Diabetes
Metab Syndr. 11 (Suppl 2):S1037–S1040. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siddeek B, Li N, Mauduit C, Chehade H,
Rigal E, Tolsa J, Armengaud J, Yzydorczyk C, Benahmed M, Vergely C
and Simeoni U: Transient postnatal over nutrition induces long-term
alterations in cardiac NLRP3-inflammasome pathway. Nutr Metab
Cardiovasc Dis. 28:944–951. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blokhin IO and Lentz SR: Mechanisms of
thrombosis in obesity. Curr Opin Hematol. 20:437–444. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Köchli S, Endes K, Infanger D, Zahner L
and Hanssen H: Obesity, blood pressure, and retinal vessels: A
meta-analysis. Pediatrics. 141:e201740902018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davis S, Nehus E, Inge T, Zhang W,
Setchell K and Mitsnefes M: Effect of bariatric surgery on urinary
sphingolipids in adolescents with severe obesity. Surg Obes Relat
Dis. 14:446–451. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hall JE, Henegar JR, Dwyer TM, Liu J, Da
Silva AA, Kuo J and Tallam L: Is obesity a major cause of chronic
kidney disease? Adv Ren Replace Ther. 11:41–54. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sowers JR: Metabolic risk factors and
renal disease. Kidney Int. 71:719–720. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cavalera M, Wang J and Frangogiannis NG:
Obesity, metabolic dysfunction, and cardiac fibrosis:
Pathophysiological pathways, molecular mechanisms, and therapeutic
opportunities. Transl Res. 164:323–335. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fang Q, Wang J, Zhang Y, Wang L, Li W, Han
J, Huang W, Liang G and Wang Y: Inhibition of myeloid
differentiation factor-2 attenuates obesity-induced cardiomyopathy
and fibrosis. Biochim Biophys Acta Mol Basis Dis. 1864:252–262.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Querejeta R, López B, González A, Sánchez
E, Larman M, Martinez Ubago JL and Díez J: Increased collagen type
I synthesis in patients with heart failure of hypertensive origin:
Relation to myocardial fibrosis. Circulation. 110:1263–1268. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ohashi K, Iwatani H, Kihara S, Nakagawa Y,
Komura N, Fujita K, Maeda N, Nishida M, Katsube F, Shimomura I, et
al: Exacerbation of albuminuria and renal fibrosis in subtotal
renal ablation model of adiponectin-knockout mice. Arterioscler
Thromb Vasc Biol. 27:1910–1917. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stokes MB, Holler S, Cui Y, Hudkins KL,
Eitner F, Fogo A and Alpers CE: Expression of decorin, biglycan,
and collagen type I in human renal fibrosing disease. Kidney Int.
57:487–498. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aleksandrova K, Mozaffarian D and Pischon
T: Addressing the perfect storm: Biomarkers in obesity and
pathophysiology of cardiometabolic risk. Clin Chem. 64:142–153.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jung HJ, Seu YB and Lee DG: Candicidal
action of resveratrol isolated from grapes on human pathogenic
yeast C. albicans. J Microbiol Biotechnol. 17:1324–1329.
2007.PubMed/NCBI
|
|
32
|
Malhotra A, Bath S and Elbarbry F: An
organ system approach to explore the antioxidative,
anti-inflammatory, and cytoprotective actions of resveratrol. Oxid
Med Cell Longev. 2015:8039712015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cucciolla V, Borriello A, Oliva A,
Galletti P, Zappia V and Della Ragione F: Resveratrol: From basic
science to the clinic. Cell Cycle. 6:2495–2510. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gambini J, Inglés M, Olaso G, Lopez-Grueso
R, Bonet-Costa V, Gimeno-Mallench L, Mas-Bargues C, Abdelaziz KM,
Gomez-Cabrera MC, Vina J and Borras C: Properties of resveratrol:
In vitro and in vivo studies about metabolism,
bioavailability, and biological effects in animal models and
humans. Oxid Med Cell Longev. 2015:8370422015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Modi S, Yaluri N and Kokkola T:
Strigolactone GR24 and pinosylvin attenuate adipogenesis and
inflammation of white adipocytes. Biochem Biophys Res Commun.
499:164–169. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aguirre L, Fernández-Quintela A, Arias N
and Portillo MP: Resveratrol: Anti-obesity mechanisms of action.
Molecules. 19:18632–18655. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baur JA and Sinclair DA: Therapeutic
potential of resveratrol: The in vivo evidence. Nat Rev Drug
Discov. 5:4932006. View Article : Google Scholar : PubMed/NCBI
|
